• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

BSA 纳米颗粒的枯否细胞阈值的研究与应用。

Research and Application of Kupffer Cell Thresholds for BSA Nanoparticles.

机构信息

Department of Pharmacy, Changhai Hospital, Naval Medical University (Second Military Medical University), Shanghai 200433, China.

Department of Gastroenterology, Changzheng Hospital, Naval Medical University (Second Military Medical University), Shanghai 200433, China.

出版信息

Molecules. 2023 Jan 16;28(2):880. doi: 10.3390/molecules28020880.

DOI:10.3390/molecules28020880
PMID:36677939
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC9864197/
Abstract

Over the past decade, the dose of nanoparticles given to solid tumors has remained at a median of 0.7% of the injected dose. Most nanoparticles are trapped in a mononuclear phagocyte system (MPS), of which 85% are Kupffer cells. In our study, threshold doses of bovine serum albumin (BSA) nanoparticles were investigated for the uptake of Kupffer cells in vitro and in vivo. The antitumor effect and safety of albumin-bound paclitaxel (ABP) were improved by using threshold doses of BSA nanoparticles. We found a threshold dose of 20,000 nanoparticles per macrophage uptake in vitro and a saturation dose of 0.3 trillion nanoparticles in tumor-bearing mice. In vivo efficacy and safety evaluations demonstrated that the threshold doses of blank BSA nanoparticles could significantly improve the efficacy and safety of ABP against tumors compared with ABP alone. In this study, the delivery efficiency of ABP was improved by using blank nanoparticles to saturate Kupffer cells, which provided a new approach to studying the Kupffer cell saturation threshold and thus a new scheme for improving the curative effect of ABP.

摘要

在过去的十年中,给予实体瘤的纳米颗粒剂量中位数一直保持在注射剂量的 0.7%。大多数纳米颗粒被单核吞噬细胞系统 (MPS) 捕获,其中 85%是库普弗细胞。在我们的研究中,研究了牛血清白蛋白 (BSA) 纳米颗粒的阈值剂量,以研究其在体外和体内对库普弗细胞的摄取。使用 BSA 纳米颗粒的阈值剂量可以提高白蛋白结合紫杉醇 (ABP) 的抗肿瘤作用和安全性。我们发现,体外每吞噬细胞摄取 20000 个纳米颗粒为阈值剂量,荷瘤小鼠的饱和剂量为 0.3 万亿个纳米颗粒。体内疗效和安全性评估表明,与单独使用 ABP 相比,空白 BSA 纳米颗粒的阈值剂量可显著提高 ABP 对肿瘤的疗效和安全性。在这项研究中,通过使用空白纳米颗粒使库普弗细胞饱和来提高 ABP 的递送效率,为研究库普弗细胞饱和阈值提供了一种新方法,从而为提高 ABP 的治疗效果提供了一种新方案。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/e30e/9864197/6e98d5467aed/molecules-28-00880-g005.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/e30e/9864197/dcbf2fdc1dd8/molecules-28-00880-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/e30e/9864197/23d243152e60/molecules-28-00880-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/e30e/9864197/b5c20ffb6250/molecules-28-00880-g003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/e30e/9864197/8c492a81fdf6/molecules-28-00880-g004.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/e30e/9864197/6e98d5467aed/molecules-28-00880-g005.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/e30e/9864197/dcbf2fdc1dd8/molecules-28-00880-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/e30e/9864197/23d243152e60/molecules-28-00880-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/e30e/9864197/b5c20ffb6250/molecules-28-00880-g003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/e30e/9864197/8c492a81fdf6/molecules-28-00880-g004.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/e30e/9864197/6e98d5467aed/molecules-28-00880-g005.jpg

相似文献

1
Research and Application of Kupffer Cell Thresholds for BSA Nanoparticles.BSA 纳米颗粒的枯否细胞阈值的研究与应用。
Molecules. 2023 Jan 16;28(2):880. doi: 10.3390/molecules28020880.
2
Pharmacokinetic analysis of lectin-dependent biodistribution of fucosylated bovine serum albumin: a possible carrier for Kupffer cells.岩藻糖基化牛血清白蛋白凝集素依赖性生物分布的药代动力学分析:一种可能的库普弗细胞载体。
J Drug Target. 2001;9(5):341-51. doi: 10.3109/10611860108998770.
3
Lipoprotein-Inspired Nanocarrier Composed of Folic Acid-Modified Protein and Lipids: Preparation and Evaluation of Tumor-Targeting Effect.基于脂蛋白的纳米载体,由叶酸修饰的蛋白质和脂质组成:制备及肿瘤靶向效果评价。
Int J Nanomedicine. 2020 May 14;15:3433-3445. doi: 10.2147/IJN.S241448. eCollection 2020.
4
Long-circulating self-assembled cholesteryl albumin nanoparticles enhance tumor accumulation of hydrophobic anticancer drug.长循环自组装胆固醇基白蛋白纳米粒增强疏水性抗癌药物的肿瘤蓄积
Eur J Pharm Biopharm. 2015 Oct;96:96-105. doi: 10.1016/j.ejpb.2015.07.013. Epub 2015 Jul 23.
5
An organic solvent-free technology for the fabrication of albumin-based paclitaxel nanoparticles for effective cancer therapy.无有机溶剂技术制备基于白蛋白的紫杉醇纳米粒用于有效癌症治疗。
Colloids Surf B Biointerfaces. 2019 Nov 1;183:110394. doi: 10.1016/j.colsurfb.2019.110394. Epub 2019 Jul 31.
6
Tumor-targeting and pH-sensitive lipoprotein-mimic nanocarrier for targeted intracellular delivery of paclitaxel.用于紫杉醇靶向细胞内递送的肿瘤靶向和 pH 敏感脂蛋白模拟纳米载体。
Int J Pharm. 2015 Mar 1;480(1-2):116-27. doi: 10.1016/j.ijpharm.2015.01.036. Epub 2015 Jan 20.
7
Uptake characteristics of mannosylated and fucosylated bovine serum albumin in primary cultured rat sinusoidal endothelial cells and Kupffer cells.甘露糖化和岩藻糖化牛血清白蛋白在原代培养大鼠窦状内皮细胞和库普弗细胞中的摄取特性
Int J Pharm. 2004 Dec 9;287(1-2):147-54. doi: 10.1016/j.ijpharm.2004.08.021.
8
An arginine derivative contained nanostructure lipid carriers with pH-sensitive membranolytic capability for lysosomolytic anti-cancer drug delivery.载有精氨酸衍生物的具有 pH 敏感性的溶膜能力的纳米结构脂质载体,用于溶酶体裂解抗癌药物递送。
Int J Pharm. 2012 Oct 15;436(1-2):248-57. doi: 10.1016/j.ijpharm.2012.06.040. Epub 2012 Jun 23.
9
Drug-binding albumins forming stabilized nanoparticles for efficient anticancer therapy.形成稳定纳米颗粒的药物结合白蛋白用于高效抗癌治疗。
Nanomedicine. 2019 Oct;21:102058. doi: 10.1016/j.nano.2019.102058. Epub 2019 Jul 22.
10
Drug-binding albumins forming stabilized nanoparticles for co-delivery of paclitaxel and resveratrol: In vitro/in vivo evaluation and binding properties investigation.载药白蛋白纳米粒共载紫杉醇和白藜芦醇:体内外评价及结合特性研究。
Int J Biol Macromol. 2020 Jun 15;153:873-882. doi: 10.1016/j.ijbiomac.2020.03.060. Epub 2020 Mar 10.

引用本文的文献

1
[Research progress of coarse-grained molecular dynamics in drug carrier materials].[粗粒度分子动力学在药物载体材料中的研究进展]
Sheng Wu Yi Xue Gong Cheng Xue Za Zhi. 2023 Aug 25;40(4):799-804. doi: 10.7507/1001-5515.202303008.

本文引用的文献

1
Liver macrophages in health and disease.肝脏巨噬细胞在健康和疾病中的作用。
Immunity. 2022 Sep 13;55(9):1515-1529. doi: 10.1016/j.immuni.2022.08.002.
2
Why nanoparticles prefer liver macrophage cell uptake in vivo.为什么纳米颗粒在体内更倾向于被肝巨噬细胞摄取。
Adv Drug Deliv Rev. 2022 Jun;185:114238. doi: 10.1016/j.addr.2022.114238. Epub 2022 Mar 31.
3
Immunologically modified enzyme-responsive micelles regulate the tumor microenvironment for cancer immunotherapy.免疫修饰的酶响应性胶束调节肿瘤微环境用于癌症免疫治疗。
Mater Today Bio. 2021 Dec 4;13:100170. doi: 10.1016/j.mtbio.2021.100170. eCollection 2022 Jan.
4
Tumor-Associated-Macrophage-Membrane-Coated Nanoparticles for Improved Photodynamic Immunotherapy.肿瘤相关巨噬细胞膜包覆的纳米颗粒用于改善光动力学免疫治疗。
Nano Lett. 2021 Jul 14;21(13):5522-5531. doi: 10.1021/acs.nanolett.1c00818. Epub 2021 Jun 16.
5
Nanotechnology for modern medicine: next step towards clinical translation.纳米技术在现代医学中的应用:迈向临床转化的下一步。
J Intern Med. 2021 Sep;290(3):486-498. doi: 10.1111/joim.13254. Epub 2021 Mar 31.
6
Collagenase IV and clusterin-modified polycaprolactone-polyethylene glycol nanoparticles for penetrating dense tumor tissues.胶原酶 IV 和簇集素修饰的聚己内酯-聚乙二醇纳米粒用于穿透致密肿瘤组织。
Theranostics. 2021 Jan 1;11(2):906-924. doi: 10.7150/thno.47446. eCollection 2021.
7
A framework for designing delivery systems.设计传递系统的框架。
Nat Nanotechnol. 2020 Oct;15(10):819-829. doi: 10.1038/s41565-020-0759-5. Epub 2020 Sep 7.
8
The dose threshold for nanoparticle tumour delivery.纳米颗粒肿瘤递呈的剂量阈值。
Nat Mater. 2020 Dec;19(12):1362-1371. doi: 10.1038/s41563-020-0755-z. Epub 2020 Aug 10.
9
An Analysis of the Binding Function and Structural Organization of the Protein Corona.蛋白质冠层的结合功能与结构组织分析
J Am Chem Soc. 2020 May 13;142(19):8827-8836. doi: 10.1021/jacs.0c01853. Epub 2020 Apr 28.
10
Chemotaxis-driven delivery of nano-pathogenoids for complete eradication of tumors post-phototherapy.化学趋性驱动的纳米病原体递呈用于光疗后完全消除肿瘤
Nat Commun. 2020 Feb 28;11(1):1126. doi: 10.1038/s41467-020-14963-0.